83 FR 16370 - Findings of Research Misconduct

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Federal Register Volume 83, Issue 73 (April 16, 2018)

Page Range		16370-16371
FR Document		2018-07782

Notice is hereby given that on April 2, 2018, the Department of Health and Human Services (HHS) Debarring Official, on behalf of the Secretary of HHS, issued a final notice of debarment based on the findings of research misconduct made by the Office of Research Integrity (ORI) against H.M. Krishna Murthy, Ph.D., former Research Associate Professor, Department of Vision Sciences, University of Alabama at Birmingham (UAB). Dr. Murthy engaged in research misconduct in research supported by U.S. Public Health Service (PHS) grants, specifically National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), grants R01 AI051615, R01 AI032078, and R01 AI045623; National Heart, Lung, and Blood Institute (NHLBI), NIH, grants P01 HL034343 and R01 HL064272; and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, grant R01 DK046900. The administrative actions, including ten (10) years of debarment, were implemented beginning on April 2, 2018, and are detailed below.

Federal Register, Volume 83 Issue 73 (Monday, April 16, 2018)

[Federal Register Volume 83, Number 73 (Monday, April 16, 2018)]
[Notices]
[Pages 16370-16371]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-07782]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that on April 2, 2018, the Department 
of Health and Human Services (HHS) Debarring Official, on behalf of the 
Secretary of HHS, issued a final notice of debarment based on the 
findings of research misconduct made by the Office of Research 
Integrity (ORI) against H.M. Krishna Murthy, Ph.D., former Research 
Associate Professor, Department of Vision Sciences, University of 
Alabama at Birmingham (UAB).
    Dr. Murthy engaged in research misconduct in research supported by 
U.S. Public Health Service (PHS) grants, specifically National 
Institute of Allergy and Infectious Diseases (NIAID), National 
Institutes of Health (NIH), grants R01 AI051615, R01 AI032078, and R01 
AI045623; National Heart, Lung, and Blood Institute (NHLBI), NIH, 
grants P01 HL034343 and R01 HL064272; and National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, grant R01 
DK046900. The administrative actions, including ten (10) years of 
debarment, were implemented beginning on April 2, 2018, and are 
detailed below.

FOR FURTHER INFORMATION CONTACT:  Wanda K. Jones, Dr.P.H., Interim 
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that HHS has taken 
final action in the following case:
    H.M. Krishna Murthy, Ph.D., University of Alabama at Birmingham: 
Based on evidence and findings of an investigation conducted by UAB, 
ORI's review of UAB's investigation, and additional evidence obtained 
and analysis conducted by ORI in its oversight review of UAB's 
investigation, ORI found that Dr. H.M. Krishna Murthy (Respondent), 
former Research Associate Professor, Department of Vision Sciences, 
UAB, committed research misconduct in research supported by PHS grants, 
specifically NIAID, NIH, grants R01 AI051615, R01 AI032078, and R01 
AI045623; NHLBI, NIH, grants P01 HL034343 and R01 HL064272; and NIDDK, 
NIH, grant R01 DK046900.
    Falsified and/or fabricated research was reported in:

 Nature 444:221-225, 2006 (hereafter referred to as ``Nature 
2006''); retracted in: Nature 532:268, 2016 April 14
 J. Biol. Chem. 274:5573-5580, 1999 (hereafter referred to 
as ``J. Biol. Chem. 1999''); retracted in: J. Biol. Chem. 284:34468, 
2009
 Proc. Natl. Acad. Sci. USA 101:8924-8929, 2004 (hereafter 
referred to as ``PNAS 2004''); Editorial Expression of Concern in: 
PNAS 107:6551, 2010 April 6
 Biochem. 44:10757-10765, 2005 (hereafter referred to as 
``Biochem. 2005'')
 Proc. Natl. Acad. Sci. USA 103:2126-2131, 2006 (hereafter 
referred to as ``PNAS 2006''); Editorial Expression of Concern in: 
PNAS 107:6551, 2010 April 6
 Acta Cryst. D55:1971-1977, 1999 (hereafter referred to as 
``Acta Cryst. 1999''); retracted in: Acta Cryst. D66:222, 2010
 J. Mol. Biol. 301:759-767, 2000 (hereafter referred to as 
``J. Mol. Biol. 2000''); retracted in: J. Mol. Biol. 397:1119, 2010
 Cell 104:301-311, 2001 (hereafter referred to as ``Cell 
2001'')
 Biochem. 41:11681-11691, 2002 (hereafter referred to as 
``Biochem. 2002'')
 Protein Data Bank (PDB) identification codes 2HR0, 1BEF, 
1RID, 1Y8E, 2A01, 1CMW, 2QID, 1DF9, 1G40, 1G44, 2OU1, and 1L6L (the 
PDB is funded in part by NIH)

    Falsified and/or fabricated research results also were 
referenced in the following PHS grant applications:

 1 R21 AI056224-01 submitted to NIAID, NIH
 1 R01 AI064509-01 submitted to NIAID, NIH
 1 R01 AI64509-01A1 submitted to NIAID, NIH
 1 R01 AI051615-01A1 submitted to NIAID, NIH
 1 R03 TW006840-01 submitted to Fogarty International Center 
(FIC), NIH


[[Page 16371]]


    ORI found by a preponderance of the evidence that Respondent 
intentionally, knowingly, or recklessly engaged in research misconduct 
by falsifying and/or fabricating X-ray crystallographic data for eleven 
(11) protein structures and falsely reporting them as experimentally 
derived from X-ray diffraction experiments in nine (9) publications and 
in twelve (12) deposits in the PDB. ORI found that Respondent 
intentionally, knowingly, or recklessly falsified and/or fabricated the 
PDB coordinate files deposited for all of the eleven (11) structures 
(PDB entries 2HR0, 1BEF, 1RID, 1Y8E, 2A01, 1CMW, 1G40, 1G44, 2OU1, 
1L6L, 2QID, and 1DF9) and the X-ray diffraction data (structure 
factors) corresponding to six (6) of the eleven (11) structures (PDB 
entries 2HR0, 1BEF, 1RID, 1Y8E, 2A01, and 1CMW).
    Specifically, Respondent falsified and/or fabricated:

 The protein crystal structure of complement component C3b 
reported in Nature 2006 and the corresponding structure factors and 
coordinate file deposited in the PDB for entry 2HR0
 the protein crystal structure of dengue virus NS3 serine 
protease reported in J. Biol. Chem. 1999 and the corresponding 
structure factors and coordinate file deposited in the PDB for entry 
1BEF
 the protein crystal structure of vaccinia virus complement 
control protein (VCP) in complex with heparin reported in PNAS 2004 and 
the corresponding structure factors and coordinate file deposited in 
the PDB for entry 1RID
 the protein crystal structure of VCP in complex with suramin 
(VCP-suramin) reported in Biochem. 2005 and the corresponding structure 
factors and coordinate file deposited in the PDB for entry 1Y8E
 the protein crystal structure of apolipoprotein A-I reported 
in PNAS 2006 and the corresponding structure factors and coordinate 
file deposited in the PDB for entry 2A01
 the protein crystal structure of Taq DNA polymerase reported 
in Acta Cryst. 1999 and the corresponding structure factors and 
coordinate file deposited in the PDB for entry 1CMW
 the protein crystal structure of VCP crystal form I reported 
in Cell 2001 and the corresponding coordinate files deposited in the 
PDB for entry 1G40
 the protein crystal structure of VCP crystal form II reported 
in Cell 2001 and the corresponding coordinate file deposited in the PDB 
for entry 1G44
 the protein crystal structure of apolipoprotein A-II reported 
in Biochem. 2002 and the corresponding coordinate file deposited in the 
PDB for entry 2OU1
 the protein crystal structure of apolipoprotein A-II in 
complex with [beta]-octyl glucoside reported in Biochem. 2002 and the 
corresponding coordinate file deposited in the PDB for entry IL6L
 the protein crystal structure of dengue virus NS3 protease in 
complex with a Bowman-Birk inhibitor reported in J. Mol. Biol. 2000 and 
the corresponding coordinate files deposited in the PDB for entries 
2QID and 1DF9

    ORI issued a charge letter enumerating the above findings of 
research misconduct and proposing HHS administrative actions. 
Respondent subsequently requested a hearing before an Administrative 
Law Judge (ALJ) of the Departmental Appeals Board to dispute these 
findings. ORI filed a motion for summary judgment, which Respondent 
opposed. On January 19, 2018, the ALJ issued a recommended decision to 
the Acting Assistant Secretary for Health (ASH) granting summary 
judgment in favor of ORI and sustaining ORI's proposal to impose a ten-
year debarment and a ten-year ban on PHS advisory services against 
Respondent as well as correction of Respondent's research record. The 
Acting ASH served a copy of the ALJ's recommended decision on the HHS 
Debarring Official pursuant to 42 CFR 93.523(c), and the decision 
constituted the findings of fact to the HHS Debarring Official in 
accordance with 2 CFR 180.845(c). On April 2, 2018, the HHS Debarring 
Official issued a final notice of debarment to begin on April 2, 2018, 
and end on April 1, 2028. Thus, the research misconduct findings set 
forth above became effective, and the following administrative actions 
have been implemented, beginning on April 2, 2018:
    (1) Dr. Murthy is debarred for a period of ten (10) years from 
eligibility for any contracting or subcontracting with any agency of 
the United States Government and from eligibility for or involvement in 
nonprocurement programs of the United States Government, referred to as 
``covered transactions,'' pursuant to HHS' Implementation (2 CFR part 
376) of Office of Management and Budget (OMB) Guidelines to Agencies on 
Governmentwide Debarment and Suspension (2 CFR part 180);
    (2) Dr. Murthy is prohibited from serving in any advisory capacity 
to PHS including, but not limited to, service on any PHS advisory 
committee, board, and/or peer review committee, or as a consultant for 
a period of ten (10) years; and
    (3) ORI will send a notice to the pertinent journals of the 
following publications that require retraction or correction and to the 
PDB for the following entries that require obsolescence, in accordance 
with 42 CFR 93.407(a)(1) and 93.411(b):

--Cell 104:301-311, 2001
--Biochem. 41:11681-11691, 2002
--Proc. Natl. Acad. Sci. USA 101:8924-8929, 2004
--Biochem. 44:10757-10765, 2005
--Proc. Natl. Acad. Sci. USA 103:2126-2131, 2006
--PDB entries 1RID, 1Y8E, 2A01, 1G40, 1G44, 2OU1, and 1L6L

Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018-07782 Filed 4-13-18; 8:45 am]
 BILLING CODE 4150-31-P

16370 Federal Register / Vol. 83, No. 73 / Monday, April 16, 2018 / Notices

requests. See the SUPPLEMENTARY dietary supplements containing caffeine 1101 Wootton Parkway, Suite 750,
INFORMATION section for electronic that do not present a significant or Rockville, MD 20852, (240) 453–8200.
access to the guidance document. unreasonable risk of illness or injury. SUPPLEMENTARY INFORMATION: Notice is
FOR FURTHER INFORMATION CONTACT: The guidance represents our current hereby given that HHS has taken final
Sibyl Swift, Office of Dietary thinking on dietary supplements action in the following case:
Supplement Programs, Center for Food containing high concentrations of
caffeine. It does not establish any rights H.M. Krishna Murthy, Ph.D.,
Safety and Applied Nutrition, Food and
for any person and is not binding on University of Alabama at Birmingham:
Drug Administration, 5001 Campus Dr.,
FDA or the public. You can use an Based on evidence and findings of an
College Park, MD 20740, 240–402–1455.
alternative approach if it satisfies the investigation conducted by UAB, ORI’s
SUPPLEMENTARY INFORMATION: review of UAB’s investigation, and
requirements of the applicable statutes
I. Background and regulations. This guidance is not additional evidence obtained and
subject to Executive Order 12866. analysis conducted by ORI in its
We are announcing the availability of oversight review of UAB’s investigation,
a guidance for industry entitled ‘‘Highly II. Electronic Access ORI found that Dr. H.M. Krishna Murthy
Concentrated Caffeine in Dietary (Respondent), former Research
Supplements.’’ We are issuing this Persons with access to the internet
may obtain the document at either Associate Professor, Department of
guidance consistent with our good Vision Sciences, UAB, committed
guidance practices (GGP) regulation 21 https://www.fda.gov/FoodGuidances or
https://www.regulations.gov. research misconduct in research
CFR 10.115. In accordance with 21 CFR supported by PHS grants, specifically
§ 10.115(g)(2), we are issuing this Dated: April 11, 2018. NIAID, NIH, grants R01 AI051615, R01
guidance without prior public comment Leslie Kux, AI032078, and R01 AI045623; NHLBI,
because we have determined that prior Associate Commissioner for Policy. NIH, grants P01 HL034343 and R01
public participation is not feasible or [FR Doc. 2018–07836 Filed 4–13–18; 8:45 am] HL064272; and NIDDK, NIH, grant R01
appropriate in light of the threat to the DK046900.
BILLING CODE 4164–01–P
public health that is posed by pure and
highly concentrated caffeine products, Falsified and/or fabricated research
which have been linked to several was reported in:
DEPARTMENT OF HEALTH AND
deaths in recent years. Although this HUMAN SERVICES • Nature 444:221–225, 2006 (hereafter
guidance is immediately in effect, it referred to as ‘‘Nature 2006’’); retracted in:
remains subject to comment in Office of the Secretary Nature 532:268, 2016 April 14
accordance with FDA’s GGP regulation. • J. Biol. Chem. 274:5573–5580, 1999
Findings of Research Misconduct (hereafter referred to as ‘‘J. Biol. Chem.
In this guidance, we are announcing
1999’’); retracted in: J. Biol. Chem.
that we consider some dietary 284:34468, 2009
supplements containing high AGENCY: Office of the Secretary, HHS.
• Proc. Natl. Acad. Sci. USA 101:8924–8929,
concentrations of caffeine to be ACTION: Notice. 2004 (hereafter referred to as ‘‘PNAS
adulterated and informing industry 2004’’); Editorial Expression of Concern in:
about characteristics that are likely to SUMMARY: Notice is hereby given that on PNAS 107:6551, 2010 April 6
lead to products being considered April 2, 2018, the Department of Health • Biochem. 44:10757–10765, 2005 (hereafter
adulterated. A dietary supplement is and Human Services (HHS) Debarring referred to as ‘‘Biochem. 2005’’)
adulterated under section 402(f)(1)(A) of Official, on behalf of the Secretary of • Proc. Natl. Acad. Sci. USA 103:2126–2131,
HHS, issued a final notice of debarment 2006 (hereafter referred to as ‘‘PNAS
the FD&C Act (21 U.S.C. 342(f)(1)(A)) if
based on the findings of research 2006’’); Editorial Expression of Concern in:
it presents a significant or unreasonable PNAS 107:6551, 2010 April 6
risk of illness or injury under the misconduct made by the Office of
Research Integrity (ORI) against H.M. • Acta Cryst. D55:1971–1977, 1999 (hereafter
conditions of use recommended or referred to as ‘‘Acta Cryst. 1999’’); retracted
suggested in the labeling or, if no Krishna Murthy, Ph.D., former Research in: Acta Cryst. D66:222, 2010
conditions for use are suggested or Associate Professor, Department of • J. Mol. Biol. 301:759–767, 2000 (hereafter
recommended, under ordinary Vision Sciences, University of Alabama referred to as ‘‘J. Mol. Biol. 2000’’);
conditions of use. In recent years, we at Birmingham (UAB). retracted in: J. Mol. Biol. 397:1119, 2010
have seen the emergence of powdered Dr. Murthy engaged in research • Cell 104:301–311, 2001 (hereafter referred
misconduct in research supported by to as ‘‘Cell 2001’’)
and liquid dietary supplement products
U.S. Public Health Service (PHS) grants, • Biochem. 41:11681–11691, 2002 (hereafter
containing high concentrations of referred to as ‘‘Biochem. 2002’’)
caffeine marketed directly to consumers. specifically National Institute of Allergy
• Protein Data Bank (PDB) identification
These products are often sold in bulk and Infectious Diseases (NIAID),
codes 2HR0, 1BEF, 1RID, 1Y8E, 2A01,
containers with hundreds or thousands National Institutes of Health (NIH), 1CMW, 2QID, 1DF9, 1G40, 1G44, 2OU1,
of servings in the container, and even a grants R01 AI051615, R01 AI032078, and 1L6L (the PDB is funded in part by
small dose can be toxic or deadly. The and R01 AI045623; National Heart, NIH)
consumer is required to measure out a Lung, and Blood Institute (NHLBI), NIH, Falsified and/or fabricated research results
small, precise serving from what is often grants P01 HL034343 and R01 also were referenced in the following PHS
a potentially lethal amount of product. HL064272; and National Institute of grant applications:
These products pose a significant or Diabetes and Digestive and Kidney • 1 R21 AI056224–01 submitted to NIAID,
unreasonable risk of illness or injury. Diseases (NIDDK), NIH, grant R01 NIH
srobinson on DSK3G9T082PROD with NOTICES

When formulated appropriately, DK046900. The administrative actions, • 1 R01 AI064509–01 submitted to NIAID,
caffeine can be an ingredient in a including ten (10) years of debarment, NIH
were implemented beginning on April • 1 R01 AI64509–01A1 submitted to NIAID,
dietary supplement that does not NIH
present a significant or unreasonable 2, 2018, and are detailed below.
• 1 R01 AI051615–01A1 submitted to NIAID,
risk of illness or injury. The guidance FOR FURTHER INFORMATION CONTACT: NIH
provides suggestions on how Wanda K. Jones, Dr.P.H., Interim • 1 R03 TW006840–01 submitted to Fogarty
manufacturers can formulate safer Director, Office of Research Integrity, International Center (FIC), NIH

VerDate Sep<11>2014 19:42 Apr 13, 2018 Jkt 244001 PO 00000 Frm 00086 Fmt 4703 Sfmt 4703 E:\FR\FM\16APN1.SGM 16APN1

Federal Register / Vol. 83, No. 73 / Monday, April 16, 2018 / Notices 16371

ORI found by a preponderance of the Biochem. 2002 and the corresponding (3) ORI will send a notice to the
evidence that Respondent intentionally, coordinate file deposited in the PDB pertinent journals of the following
knowingly, or recklessly engaged in for entry 2OU1 publications that require retraction or
research misconduct by falsifying and/ • the protein crystal structure of correction and to the PDB for the
or fabricating X-ray crystallographic apolipoprotein A–II in complex with following entries that require
data for eleven (11) protein structures b-octyl glucoside reported in obsolescence, in accordance with 42
and falsely reporting them as Biochem. 2002 and the corresponding CFR 93.407(a)(1) and 93.411(b):
experimentally derived from X-ray coordinate file deposited in the PDB —Cell 104:301–311, 2001
diffraction experiments in nine (9) for entry IL6L —Biochem. 41:11681–11691, 2002
publications and in twelve (12) deposits • the protein crystal structure of dengue —Proc. Natl. Acad. Sci. USA 101:8924–
in the PDB. ORI found that Respondent virus NS3 protease in complex with a 8929, 2004
intentionally, knowingly, or recklessly Bowman-Birk inhibitor reported in J. —Biochem. 44:10757–10765, 2005
falsified and/or fabricated the PDB Mol. Biol. 2000 and the corresponding —Proc. Natl. Acad. Sci. USA 103:2126–
coordinate files deposited for all of the coordinate files deposited in the PDB 2131, 2006
eleven (11) structures (PDB entries for entries 2QID and 1DF9 —PDB entries 1RID, 1Y8E, 2A01, 1G40,
2HR0, 1BEF, 1RID, 1Y8E, 2A01, 1CMW, ORI issued a charge letter 1G44, 2OU1, and 1L6L
1G40, 1G44, 2OU1, 1L6L, 2QID, and enumerating the above findings of Wanda K. Jones,
1DF9) and the X-ray diffraction data research misconduct and proposing Interim Director, Office of Research Integrity.
(structure factors) corresponding to six HHS administrative actions. Respondent
[FR Doc. 2018–07782 Filed 4–13–18; 8:45 am]
(6) of the eleven (11) structures (PDB subsequently requested a hearing before
BILLING CODE 4150–31–P
entries 2HR0, 1BEF, 1RID, 1Y8E, 2A01, an Administrative Law Judge (ALJ) of
and 1CMW). the Departmental Appeals Board to
Specifically, Respondent falsified dispute these findings. ORI filed a
DEPARTMENT OF HEALTH AND
and/or fabricated: motion for summary judgment, which
HUMAN SERVICES
• The protein crystal structure of Respondent opposed. On January 19,
complement component C3b reported 2018, the ALJ issued a recommended Indian Health Service
in Nature 2006 and the corresponding decision to the Acting Assistant
structure factors and coordinate file Secretary for Health (ASH) granting Indian Health Professions Preparatory,
deposited in the PDB for entry 2HR0 summary judgment in favor of ORI and Indian Health Professions Pre-
• the protein crystal structure of dengue sustaining ORI’s proposal to impose a Graduate and Indian; Health
virus NS3 serine protease reported in ten-year debarment and a ten-year ban Professions Scholarship Programs
J. Biol. Chem. 1999 and the on PHS advisory services against
corresponding structure factors and Respondent as well as correction of Announcement Type: Initial
CFDA Numbers: 93.971, 93.123, and 93.972
coordinate file deposited in the PDB Respondent’s research record. The
for entry 1BEF Acting ASH served a copy of the ALJ’s Key Dates
• the protein crystal structure of recommended decision on the HHS Application Deadline Date: April 13,
vaccinia virus complement control Debarring Official pursuant to 42 CFR 2018, 7:00 p.m. Eastern for continuing
protein (VCP) in complex with 93.523(c), and the decision constituted students
heparin reported in PNAS 2004 and the findings of fact to the HHS Application Deadline Date: April 13,
the corresponding structure factors Debarring Official in accordance with 2 2018, 7:00 p.m. Eastern for new
and coordinate file deposited in the CFR 180.845(c). On April 2, 2018, the students
PDB for entry 1RID HHS Debarring Official issued a final Application Review Date: May 7–25,
• the protein crystal structure of VCP in notice of debarment to begin on April 2, 2018
complex with suramin (VCP-suramin) 2018, and end on April 1, 2028. Thus, Continuation Award Notification
reported in Biochem. 2005 and the the research misconduct findings set Deadline Date: June 5, 2018
corresponding structure factors and forth above became effective, and the New Award Notification Deadline Date:
coordinate file deposited in the PDB following administrative actions have July 15, 2018
for entry 1Y8E been implemented, beginning on April Award Start Date: August 1, 2018
• the protein crystal structure of 2, 2018: Acceptance/Decline of Awards Deadline
apolipoprotein A–I reported in PNAS (1) Dr. Murthy is debarred for a period Date: August 15, 2018
2006 and the corresponding structure of ten (10) years from eligibility for any
contracting or subcontracting with any I. Funding Opportunity Description
factors and coordinate file deposited
in the PDB for entry 2A01 agency of the United States Government The Indian Health Service (IHS) is
• the protein crystal structure of Taq and from eligibility for or involvement committed to encouraging American
DNA polymerase reported in Acta in nonprocurement programs of the Indians and Alaska Natives to enter the
Cryst. 1999 and the corresponding United States Government, referred to as health professions and to assuring the
structure factors and coordinate file ‘‘covered transactions,’’ pursuant to availability of Indian health
deposited in the PDB for entry 1CMW HHS’ Implementation (2 CFR part 376) professionals to serve Indians. The IHS
• the protein crystal structure of VCP of Office of Management and Budget is committed to the recruitment of
crystal form I reported in Cell 2001 (OMB) Guidelines to Agencies on students for the following programs:
and the corresponding coordinate Governmentwide Debarment and • The Indian Health Professions
files deposited in the PDB for entry Suspension (2 CFR part 180); Preparatory Scholarship (Preparatory
srobinson on DSK3G9T082PROD with NOTICES

1G40 (2) Dr. Murthy is prohibited from Scholarship) authorized by Section 103
• the protein crystal structure of VCP serving in any advisory capacity to PHS of the Indian Health Care Improvement
crystal form II reported in Cell 2001 including, but not limited to, service on Act, Public Law 94–437 (1976), as
and the corresponding coordinate file any PHS advisory committee, board, amended (IHCIA), codified at 25 U.S.C.
deposited in the PDB for entry 1G44 and/or peer review committee, or as a 1613(b)(1).
• the protein crystal structure of consultant for a period of ten (10) years; • The Indian Health Professions Pre-
apolipoprotein A–II reported in and graduate Scholarship (Pre-graduate

VerDate Sep<11>2014 19:42 Apr 13, 2018 Jkt 244001 PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 E:\FR\FM\16APN1.SGM 16APN1

Document Created: 2018-04-14 02:19:16
Document Modified: 2018-04-14 02:19:16

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Wanda K. Jones, Dr.P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.
FR Citation		83 FR 16370

83 FR 16370 - Findings of Research Misconduct

DEPARTMENT OF HEALTH AND HUMAN SERVICESOffice of the Secretary

Federal Register Volume 83, Issue 73 (April 16, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary